Our Technology Partn3Ring webinars showcase technologies with 3Rs potential to the wider scientific community to identify new partners for further development, qualification and use. Webinars consist of short pitches outlining the 3Rs technologies and unique opportunities for collaboration.
The next Technology Partn3Ring webinar topic will be delivered as a fortnightly webinar series between April and July 2026, reflecting the interest from researchers and technology developers working in new approach methodologies (NAMs), which are replacement technologies for use in assessing chemical or drug toxicity.
The series is open to researchers, clinicians, pharmaceutical and industry professionals. Audience members will be able to ask questions to the speakers and connect with the speakers to access unique collaboration opportunities.
On this page:
- Upcoming dates, open for registration
- Recordings of previous sessions (available shortly after the session)
Upcoming webinars, open for registration:
Register for session 6: Wednesday 15 July, 14.00 - 15.15 (BST)
The sixth session speakers will showcase a genetically engineered lung cancer model, an embryonic zebrafish assay for developmental toxicity, lab-grown musculoskeletal tissues and human cardiac and multi-tissue safety screening assays.
Carlos Lopez-Garcia (Bangor University)
- Carlos's group models lung squamous cell carcinoma by genetically manipulating human bronchial epithelial cells, recapitulating both preinvasive and invasive stages of the disease.
- Carlos is seeking collaborators with organ-on-a-chip platforms, real-time air-liquid interface imaging, or automated media-replacement systems, to monitor invasion and cancer-stromal-immune interactions.
Arantza Muriana (BBD BioPhenix / Biobide)
- Biobide have paired zebrafish embryo assays with multi-omics to predict teratogenicity, generating human-relevant mechanistic data for weight-of-evidence developmental toxicity assessment.
- Arantza is looking for a partner with transcriptomics experience to combine with Biobide's zebrafish capability and validate both reference compounds and the company's own products.
Sanne Holt (Ncardia Services B.V.)
- Ncardia has developed an iPSC-derived, seven-tissue functional safety screening platform and kinetic cardiac profiling, demonstrated through case studies on antibody-drug conjugates and kinase inhibitors.
- Sanne wants to connect with partners to refine the platform and explore how to deploy it widely to support companies' investigational new drug applications.
Andrew Capel (Myomaker Bio)
- Myomaker Bio has developed lab-grown musculoskeletal tissues for preclinical drug development.
- Andrew is looking for end-users to validate the platform against musculoskeletal health, injury, disease and regeneration, plus partners to develop bespoke assays for orphan diseases.
Subscribe to our NC3Rs newsletter and follow us on LinkedIn and Bluesky for the latest updates on this series. Researchers in this area can also engage with our NAMs Network that supports scientists from across sectors to establish collaborations and catalyses the uptake of 3Rs technologies.
Recordings
Recordings of sessions will be available to re-watch on this page shortly after the session along with contact details should you wish to collaborate with the speaker. They will remain live for 12 months after the date of the recording.
- Session 1: Wednesday 22 April 2026
The first NAMs webinar included presentations from four researchers working across invertebrate models as partial replacements for the use of mammals, human-relevant microphysiological models, drug efficacy and drug/consumer product toxicity testing. - Session 2: Wednesday 6 May 2026
The second NAMs webinar showcased approaches from five researchers covering brain tumour modelling, stem cell platforms in toxicity and counting, cell-based assays for safety assessment, and organ function studies. - Session 3: Wednesday 20 May 2026
The third NAMs webinar showcased approaches across in vitro approaches and models to replace the use of animals, spanning in uses in osteoarthritis, bone, liver, heart and lung assays. - Session 4: Wednesday 3 June 2026
The fourth NAMs session included presentations showcasing a synthetic hydrogel and an in vitro 3D cultivation system alongside advanced cell models for safety testing and alternative biological assays. - Session 5: Wednesday 17 June 2026
The fifth NAMs session included presentations showcasing in silico modelling approaches, a bioengineered bone organoid platform, an organ-on-chip system for inhalation toxicity assessment, and a human cardiac tissue model for preclinical drug development.
Session 1: Wednesday 22 April 2026
The first NAMs webinar included presentations from four researchers working across invertebrate models as partial replacements for the use of mammals, human-relevant microphysiological models, drug efficacy and drug/consumer product toxicity testing.
Early drug screening with C. elegans: A 3Rs-aligned approach
Karthik Mohanraj (Magnitude Biosciences Limited)
- High-throughput C. elegans platform, delivering scalable and predictive insights on drug efficacy, safety and mechanism of action.
- Seeking collaborators to further qualify screening platform and provide access to comparator datasets.
Connect with Karthik for more information about their collaboration opportunity: karthik@magnitudebiosciences.com.
From model to method: Validating C. elegans-based DART assay towards regulatory use
Matteo Cornaglia (Nagi Bioscience)
- Providing human relevant whole organism toxicity data that can replace early mammalian screens.
- Seeking collaborators for new toxicology use cases, cross‑species comparison, and standardisation towards regulatory readiness.
Connect with Matteo for more information about their collaboration opportunity: matteo.cornaglia@nagibio.ch.
Neuromuscular junction-on-a-chip: Human based assays for toxin testing and drug development aligned with FDA and NAMs regulations
Margaret Magdesian (Ananda Devices)
- Developing human iPSC‑based neuro and neuromuscular assays towards replacing animal use in neurotoxicity assays.
- Seeking partners to benchmark and expand applications, including exploring incorporation into regulatory workflows.
Connect with Margaret for more information about their collaboration opportunity: margaret@anandadevices.com.
PEVITAC: Live invertebrate models for 3Rs research
Vitaliy Khutoryanskiy (University of Reading)
- Developing invertebrate assays that can replace early-stage mammalian studies in toxicity, irritation, infection and formulation screening.
- Seeking collaborators interested in co-developing and qualifying the invertebrate-based assays for broader application and increased translational relevance.
Connect with Vitaliy for more information about their collaboration opportunity: v.khutoryanskiy@reading.ac.uk.
Session 2: Wednesday 6 May 2026
The second NAMs webinar showcased approaches from five researchers covering brain tumour modelling, stem cell platforms in toxicity and counting, cell-based assays for safety assessment, and organ function studies.
Cell-based assays for next generation development and quality control of Clostridial medicines
Ciara Doran (Sansanima Limited)
- Non-animal, cell‑based assays for safety and potency testing of Clostridials.
- Seeking partners for quality, process control or next generation development of botulinum toxin.
Connect with Ciara for more information about their collaboration opportunity: ciara.doran@sansanima.com
Neural spheroid platform to model brain tumour migration and infiltration
Davide Danovi (Migration Biotherapeutics)
- Human iPSC-based neural spheroid platform modelling tumour-brain interactions in glioblastoma.
- Looking for collaborators to further develop the model and quantify cancer cell migration.
Connect with Davide for more information about their collaboration opportunity: davidedanovi@migration.bio
Catching stem cell-toxic drugs before they cause chronic organ failure
James L. Sherley (Asymmetrex® LLC)
- Rapid, accurate counting and monitoring of tissue stem cells in heterogeneous tissue cell preparations used in in vitro drug toxicity assessment.
- Seeking collaborators to help assess predictive value of technology in drug candidates known to cause chronic organ failure.
Connect with James for more information about their collaboration opportunity: jsherley@asymmetrex.com
From screening to safety: Advancing the Membrane Proteome Array for human-relevant off-target risk assessment of biotherapeutics
Jonathan Richards (Integral Molecular)
- Human-relevant membrane proteome array to assess off-target binding of antibody-based therapies early in development.
- Seeking new users and applications of the technology to expand 3Rs benefits.
Connect with Jonathon for more information about their collaboration opportunity: jrichards@integralmolecular.com
iPSC-derived multicellular miniorgans with advanced fluorescent sensor options
Jiwu Wang (Allele Biotechnology)
- Bioprinted iPSC derived liver mini-organs to replace in vivo organ function studies in drug development.
- Seeking teams with liver specific assay expertise to further qualify the model in longitudinal studies.
Connect with Jiwu for more information about their collaboration opportunity: jiwuwang@allelebiotech.com
Session 3: Wednesday 22 April 2026
The third NAMs webinar showcased approaches across in vitro approaches and models to replace the use of animals, spanning in uses in osteoarthritisbone, liver, heart and lung assays.
An MPS aAssay for human oral bioavailability: Seeking partners to accelerate assay validation
Yassen Abbas (CN-Bio Innovations)
- CN-BIO Iinnovations develop microphysiological systems (MPS) models for drug discovery and development including liver, lung, multi-organ and immune competent models.
- Yassen is looking for partners to help further qualify the models across use cases with a particular focus on new drug modalities.
Connect with Yassen for more information about their collaboration opportunity: yassen.abbas@cn-bio.com
Precision in motion: Functional human models for the future of drug safety
Erika Ferrari (BiomimX)
- BiomimX have developed a uHeart model, a model of functional beating human cardiac tissue for cardiotoxicity and safety testing.
- Erika is seeking scientific partners to expand model validation (e.g. relevant cell providers) and partners to co-develop bespoke models for drug testing.
Connect with Erika for more information about their collaboration opportunity: erika.ferrari@biomimx.com
In vitro modelling of human osteoarthritis and tissue innervation
Abbas Ishaq (Alcyomics)
- Alcyomics have developed a human osteochondral ex vivo model, with and without innervation, generated from primary mesenchymal stem cells with the ability to include innervation and induce an model of osteoarthritic disease phenotypes.
- Looking for collaborators to further qualify their model, with the aim of establishing it as a robust, translational platform for compound screening and therapeutic development.
Connect with Abbas for more information about their collaboration opportunity: abbas.ishaq@alcyomics.com
morph_ONE, a high-content imaging-based safety screening tool designed to detect direct exposure and off-target toxicities in the lung.
Vinit Pereira (ImmuONE)
- ImmuONE have developed morph_ONE, a high-content imaging-based safety screening tool designed to detect direct exposure and off-target toxicities in the lung.
- Seeking end users to apply morph_ONE as a Tier 1 lung safety screening approach, enabling early identification of direct exposure off-target toxicities.
Connect with Vinit for more information about their collaboration opportunity: vinit.pereira@immuone.com
Session 4: Wednesday 3 June 2026
The fourth NAMs webinar showcased approaches across advanced human cell models: high-throughput organoids, in vitro cardiac and liver safety testing, a synthetic hydrogel and an alternative toxicity assay.
Development of human iPSC-derived hepatocytes for drug discovery, translational research and toxicity testing
Tom Harris-Brown (bit.bio)
- bit.bio have developed ioHepatocytes, a deterministic, scalable, human iPSC-derived model engineered to enable the industrialisation of NAMs, providing a standardised foundation for highly predictive toxicology and disease modelling.
- Tom is seeking collaborators to integrate ioHepatocytes next-generation systems, ranging from advanced 2D/3D assays to complex microphysiological systems.
Connect with Tom for more information about their collaboration opportunity: tom.harris-brown@bit.bio
Scalable human organoid screening for non-animal drug testing using pillar/perfusion plate technology
Moo-Yeal Lee (Bioprinting Laboratories Inc.)
- Bioprinting Laboratories have developed a high‑throughput pillar/perfusion plate that enables dynamic 3D culture of spheroids and organoids using bidirectional flow without pumps or tubing.
- Moo-Yeal is looking for collaborators to help qualify biological relevance and define use cases as an alternative to animal models.
Connect with Moo-Yeal for more information about their collaboration opportunity: lee@3dbpl.com
The fertilized avian egg as a partial replacement for genotoxicity testing of environmental chemicals
Tetyana Cheairs (New York Medical College)
- A fertilised avian egg model to partially replace the use of animals in the safety assessment of environmental chemicals.
- Tetyana is seeking collaborators for inter‑laboratory validation and expansion of tested substances and endpoints.
Connect with Tetyana for more information about their collaboration opportunity: tetyana_kobets@nymc.edu
DyNAtrix: Programmable viscoelastic matrices for advanced organoid culture and mechanobiology
Krishna Gupta (Leibniz Institute of Polymer Research, Dresden/Dynamic Matrices i.G.)
- DyANitrix is a non-animal synthetic hydrogel designed to better mimic dynamic human tissue mechanics in cell and organoid culture.
- Krishna is seeking pilot users in organoids, organ‑on‑chip and 3D bioprinting to support validation and qualification for toxicology and disease modelling.
Connect with Krishna for more information about their collaboration opportunity: gupta@dynamicmatrices.eu
Matthias Gossmann (innoVitro)
- innoVitro have developed the FLEXcyte 96 platform, a high-throughput in vitro system for human‑relevant cardiac safety testing through scalable, biomimetic contractility measurements.
- Matthias is seeking partners with genetically diseased human cardiac cell lines and interest in characterising their lines to support the replacement of humanised animal models of disease.
Connect with Matthias for more information about their collaboration opportunity: gossmann@innovitro.de
Session 5: Wednesday 17 June 2026
The fifth NAMs webinar showcased in silico modelling approaches, a bioengineered bone organoid platform, an organ-on-chip system for inhalation toxicity assessment and a human cardiac tissue model for preclinical drug development.
Closing the NAMs loop: Mechanism-based translation from plate to patient
Marco Siccardi (ESQlabs GmbH)
- ESQlabs develop PBPK/PBK and quantitative systems toxicology models to translate in vitro data into human exposure and effect predictions, supporting next-generation risk assessment.
- Stephan is seeking in vitro collaborators who can provide high-quality ADME and effect data to enable robust model parameterisation and ring trials across labs.
Connect with Marco for more information about their collaboration opportunity: marco.siccardi@esqlabs.com
Advancing human-relevant inhalation toxicology and building evidence for the qualification of airway-on-chip NAMs
Joyce C.Y. Huang (Anivance AI)
- Anivance AI is developing an organ-on-chip-based NAM combining airway chips, a microphysiological system, and aerosol exposure to enable human-relevant inhalation toxicity assessment, reducing reliance on animal inhalation studies.
- Joyce is seeking pharmaceutical, biotech, and NAMs-focused partners for feasibility studies, cross-laboratory evaluation, and qualification-oriented development to advance regulatory science for inhalation drug development.
Connect with Joyce for more information about their collaboration opportunity: joyce.huang@anivance.io
MetaBone: Demineralized bone paper-based in vitro bone metabolic assay platforms
Jungwoo Lee (MetaBone)
- MetaBone has developed bioengineered human bone organoids powered by Demineralized Bone Paper technology, enabling scalable, high-throughput bone metabolism experiments to replace animal use.
- Jungwoo is seeking partners for pilot studies on novel drugs targeting bone disorders and malignancies, and strategic partners with drugs of known osteogenic or haematological cytotoxicity to benchmark the platform.
Connect with Jungwoo for more information about their collaboration opportunity: jungwoo@umass.edu
QoreBiotechnologies: Validate drug modalities using real human tissue
Barrett Downing (Imperial College London)
- Imperial College London has developed a cardiac platform combining a bioreactor with living myocardial slices derived from adult human hearts, replacing and reducing animal use in preclinical drug development.
- Barrett is seeking pharmaceutical and biotechnology partners to validate the platform through efficacy and toxicity studies of novel drug candidates.
Connect with Barrett for more information about their collaboration opportunity: b.downing@imperial.ac.uk